Park Jeffrey, Suradi Hussam S
Department of Internal Medicine, Division of Cardiovascular Medicine, Rush University Medical Center Chicago, IL, US.
Card Fail Rev. 2019 Nov 4;5(3):147-154. doi: 10.15420/cfr.2019.12.2. eCollection 2019 Nov.
Heart failure (HF) is a leading cause of hospitalisation and healthcare costs worldwide. Acute decompensated heart failure accounts for more than 1 million hospitalisations in the US. Despite advances in the quality of acute and chronic HF disease management, gaps in knowledge about effective interventions to support the transition of care for patients with HF remain. Despite multiple trials of promising therapies, standard care consists of decongestion with IV diuretics and haemodynamic support with vasodilators and inotropes and this has remained largely unchanged during the past 45 years. Newer advances in medical innovations and structural heart disease interventions have now given promise to improved survival, outcomes and quality of life for patients with advanced HF of multiple aetiologies. In this article, we focus on structural interventions in the treatment of patients with HF.
心力衰竭（HF）是全球范围内住院治疗和医疗费用的主要原因。在美国，急性失代偿性心力衰竭导致的住院人数超过100万。尽管急性和慢性心力衰竭疾病管理的质量有所提高，但在支持心力衰竭患者护理过渡的有效干预措施方面，知识差距仍然存在。尽管有多项关于有前景疗法的试验，但标准治疗包括使用静脉利尿剂进行消肿以及使用血管扩张剂和正性肌力药物进行血流动力学支持，在过去45年里这在很大程度上没有改变。医学创新和结构性心脏病干预措施的新进展现在有望改善多种病因的晚期心力衰竭患者的生存率、预后和生活质量。在本文中，我们重点关注心力衰竭患者治疗中的结构性干预措施。
